Clinical trial · Observational
Study of 124I-NM404 in Advanced Solid Malignancies
A Phase 1/2 Study of 124I-NM404 in Subjects With Advanced Solid Malignancies
NCT01662284CI-TRIAL-00041812terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Sponsor determined this trial does not support their anticipated clinical development program.
Summary
Brief summary (as posted)
The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 124I-NM404 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (9)
- label
- Triple Negative Breast
- description
- 124I-NM404 in triple negative breast cancer
- interventionNames
- Drug: 124I-NM404
- label
- Prostate
- description
- 124I-NM404 in prostate cancer
- interventionNames
- Drug: 124I-NM404
- label
- Colorectal
- description
- 124I-NM404 in colorectal cancer
- interventionNames
- Drug: 124I-NM404
- label
- Gastric
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of advanced solid malignancy. * Allowed tumor types: triple negative breast, prostate, colorectal, gastric, ovarian, pancreatic, esophageal, soft tissue sarcoma, and head \& neck cancer * Disease must be at least 1cm in diameter * Brain metastasis must be stable for at least one month. * ECOG performance status 0-2 * Anticipated survival less than 5 years, as per the treating physician Exclusion Criteria: * Skin lesions only * Chemotherapy or radiotherapy within 1 week * Residual toxicities of grade 2 or greater from prior therapy * Adequate organ function as per specified laboratory parameter * Platelet count \> or = to 75,000/uL
References
Publications (0)
Data not yet available
No reference posted for this study.